The estimated Net Worth of Shawn F Mccarrey is at least 1.6 百万$ dollars as of 7 August 2018. Shawn Mccarrey owns over 55,000 units of Axogen stock worth over 1,169,397$ and over the last 12 years Shawn sold AXGN stock worth over 434,700$.
Shawn has made over 4 trades of the Axogen stock since 2013, according to the Form 4 filled with the SEC. Most recently Shawn exercised 55,000 units of AXGN stock worth 201,850$ on 7 August 2018.
The largest trade Shawn's ever made was exercising 55,000 units of Axogen stock on 7 August 2018 worth over 201,850$. On average, Shawn trades about 5,938 units every 113 days since 2013. As of 7 August 2018 Shawn still owns at least 88,057 units of Axogen stock.
You can see the complete history of Shawn Mccarrey stock trades at the bottom of the page.
Shawn's mailing address filed with the SEC is 13631 Progress Blvd #400, Alachua, FL 32615, USA.
Over the last 13 years, insiders at Axogen have traded over 73,805,978$ worth of Axogen stock and bought 504,297 units worth 3,119,117$ . The most active insiders traders include James E Deerfield Mgmt L.P....、Guido J Neels、Karen L. Zaderej. On average, Axogen executives and independent directors trade stock every 21 days with the average trade being worth of 455,132$. The most recent stock trade was executed by John Johnson on 1 September 2024, trading 11,904 units of AXGN stock currently worth 158,085$.
it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.
Axogen executives and other stock owners filed with the SEC include: